Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA. Hillmen P, et al. Among authors: maciejewski jp. Br J Haematol. 2013 Jul;162(1):62-73. doi: 10.1111/bjh.12347. Epub 2013 Apr 25. Br J Haematol. 2013. PMID: 23617322 Free PMC article. Clinical Trial.
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. Hillmen P, et al. N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648. N Engl J Med. 2006. PMID: 16990386 Free article. Clinical Trial.
Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P. Schrezenmeier H, et al. Among authors: maciejewski jp. Haematologica. 2014 May;99(5):922-9. doi: 10.3324/haematol.2013.093161. Epub 2014 Jan 31. Haematologica. 2014. PMID: 24488565 Free PMC article.
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, Maciejewski JP, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H. Brodsky RA, et al. Among authors: maciejewski jp. Haematologica. 2021 Jan 1;106(1):230-237. doi: 10.3324/haematol.2019.236877. Haematologica. 2021. PMID: 31949012 Free PMC article. Clinical Trial.
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Brodsky RA, et al. Among authors: maciejewski jp. Blood. 2008 Feb 15;111(4):1840-7. doi: 10.1182/blood-2007-06-094136. Epub 2007 Nov 30. Blood. 2008. PMID: 18055865 Free article. Clinical Trial.
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry.
Lee JW, Peffault de Latour R, Brodsky RA, Jang JH, Hill A, Röth A, Schrezenmeier H, Wilson A, Marantz JL, Maciejewski JP. Lee JW, et al. Among authors: maciejewski jp. Am J Hematol. 2019 Jan;94(1):E37-E41. doi: 10.1002/ajh.25334. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30370949 Free article. No abstract available.
524 results